Next Science (ASX:NXS) antimicrobrial solution to be sold in US

Company News

by Adrian Tan

Next Science (ASX:NXS) has received 510(k) clearance from the US Food and Drug Administration for the sale of its XPerience product in the United States.

XPerience is an antimicrobrial solution that helps prevent surgical site and post-operative infections. It is applied as a final-stage surgical rinse for open surgeries prior to closing. It is the first such solution available with no rinse out required after application. It has broad spectrum efficacy against bacteria, viruses and fungi, and offers multiple hours of protection. Next Science estimates the global addressable market at $15 billion.

Managing Director Judith Mitchell comments, “With market leading performance in pathogen reduction where bacteria like MRSA ('Golden Staph') can be eliminated so that less than 1 bacterium in a hundred million is present, we expect the product will become a first choice in the battle to reduce surgical site infection (SSI). With an estimated 234 million surgical procedures undertaken globally per annum, XPerience provides an enormous opportunity to help reduce infection, antimicrobial resistance and save lives while reducing expenses for health systems arising from postsurgical infections.”

Sales will begin immediately, using a third-party distribution network.

Shares in Next Science (ASX:NXS) are trading 23.94 per cent higher at $1.76.

Image from: https://www.nextscience.com/xperience/

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.